Abstract Library

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van Leeuwaarde R

Authors: Van Leeuwaarde R, Spada F, Cheung W, Gonzalez-Clavijo A, Pracht M,

Keywords: Quality of life, GEP-NET, EORTC QLQ-GINET21,

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,

#1642 Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: cella c

Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,

Keywords: pancreatic nets, biomarker, everolimus,